Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Explore Firm Details

European Union Food, Drugs, Healthcare, Life Sciences

Lihui Bai

Article Insights

This article from Goodwin Procter LLP is most popular:

in United Kingdom

Lihui Bai’s articles from Goodwin Procter LLP are most popular:

in United Kingdom

Goodwin Procter LLP are most popular:

within Transport topic(s)

On October 9, 2024, Bio-Thera Solutions and Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to STELARA (ustekinumab). Under the agreement, Bio-Thera will be responsible for development, manufacturing, and supply of BAT2206, and Richter will have exclusive rights to commercialize the product in the EU, the UK, Switzerland and selected other countries.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Authors

Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar

Contributor

Food, Drugs, Healthcare, Life Sciences

Contributor

United Kingdom